Inhibrx Biosciences is advancing ozekibart research in Ewing sarcoma, extending its push into rare-cancer treatment options. The company disclosed no new study details or outcomes, but said oncology development is continuing across multiple indications.
published
Inhibrx Biosciences is advancing ozekibart research in Ewing sarcoma, extending its push into rare-cancer treatment options. The company disclosed no new study details or outcomes, but said oncology development is continuing across multiple indications.
Latest documented BWB result
See Billy's timestamped results and follow-through.
Review the latest gains posts, original timestamps, and proof images published by Banking With Billy.
Historical results are not a promise of future performance. Trading involves substantial risk.This public post is a timestamped information archive, not personalized financial advice. Alerts can change as markets move. Join Billy's private group for the complete daily stream and follow-through.